Cargando…
S139: INTERIM ANALYSIS OF A REGISTRATION ENABLING STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) A CD123-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
Autores principales: | Pemmaraju, Naveen, Martinelli, Giovanni, Montesinos, Pau, Mazzarella, Luca, Deangelo, Daniel J., Erba, Harry, Sweet, Kendra, Walter, Roland, Deconinck, Eric, Legrand, Ollivier, Wang, Eunice, Aribi, Ahmed, Ulrickson, Matthew, Marconi, Giovanni, Lane, Andrew, Kantarjian, Hagop, Sloss, Callum, Malcolm, Kara, Zweidler-Mckay, Patrick, Daver, Naval |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428302/ http://dx.doi.org/10.1097/01.HS9.0000967468.85099.f4 |
Ejemplares similares
-
PB1828: CADENZA: A PIVOTAL STUDY OF PIVEKIMAB SUNIRINE (IMGN632) IN PATIENTS WITH UNTREATED/FRONTLINE BPDCN
por: Pemmaraju, N., et al.
Publicado: (2022) -
PB1888: TRIAL IN PROGRESS: PHASE 1B/2 STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) IN COMBINATION WITH VENETOCLAX/AZACITIDINE OR MAGROLIMAB FOR PATIENTS WITH CD123-POSITIVE ACUTE MYELOID LEUKEMIA (AML)
por: Daver, Naval, et al.
Publicado: (2023) -
CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia
por: Angelova, Evgeniya, et al.
Publicado: (2019) -
Allogeneic Hematopoietic Cell Transplantation for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
por: Bashir, Qaiser, et al.
Publicado: (2022) -
Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN)
por: Beird, Hannah C., et al.
Publicado: (2019)